Welcome to our dedicated page for Alto Neuroscience news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscience stock.
Alto Neuroscience Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company dedicated to redefining psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. The company's innovative Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are more likely to respond to their product candidates.
Alto's clinical-stage pipeline includes several promising drug candidates targeting various neuropsychiatric disorders such as depression, PTSD, schizophrenia, and cognitive impairments. Some of the key assets in their pipeline include ALTO-100, ALTO-202, ALTO-101, and ALTO-300, initially focusing on depressive disorders and schizophrenia populations as identified by brain-based biomarkers.
In recent news, Alto Neuroscience announced the pricing and closing of its upsized initial public offering (IPO) of over 9 million shares of common stock, generating approximately $147.9 million in gross proceeds. The company's stock began trading on the New York Stock Exchange on February 2, 2024, under the ticker symbol 'ANRO'.
Alto’s lead product candidates, ALTO-100 and ALTO-300, have shown positive Phase 2a results in major depressive disorder (MDD) trials. Enrollment is on track for Phase 2b studies, with expected data readouts in the second half of 2024 for ALTO-100 and the first half of 2025 for ALTO-300. Additionally, ALTO-101, a novel PDE4 inhibitor, has demonstrated favorable results in Phase 1, with plans to initiate a proof-of-concept study for cognitive impairment associated with schizophrenia (CIAS) in 2024.
With a robust cash position of approximately $206 million as of March 31, 2024, Alto Neuroscience is well-positioned to support its planned operations into 2027. The company is committed to advancing its mission of providing personalized treatment options for patients with neuropsychiatric conditions and delivering value to shareholders.
Alto Neuroscience (NYSE: ANRO) presented multiple studies at the 63rd ACNP annual meeting, showcasing progress in their precision psychiatry platform. The company highlighted new mechanistic findings supporting the ALTO-300 biomarker, which measures reduced neural signal stability and is linked to 5-HT2C receptor activity.
Key presentations included data on neural mechanisms of the ALTO-300 biomarker, validation of reward processing assessments for ALTO-203 trials, and findings on cognitive impairment in depression. The company announced plans for an interim analysis of the ongoing ALTO-300 Phase 2b trial in Q1 2025, with complete topline data expected in H1 2025.
Alto Neuroscience reported Q3 2024 financial results with a cash position of $182 million, expected to fund operations into 2027. The company announced topline data expectations from two MDD trials in H1 2025 for ALTO-300 and ALTO-203. While the ALTO-100 Phase 2b study in MDD did not meet its primary endpoint, it showed promising results in adjunctive treatment. R&D expenses increased to $13.1 million from $8.0 million YoY, while G&A expenses rose to $5.8 million from $1.8 million. Net loss widened to $16.8 million compared to $9.1 million in Q3 2023.
Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in two major investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18 at 3:00 pm ET, and the Jefferies London Healthcare Conference on November 20 at 3:00 pm GMT. Both events will feature fireside chats and one-on-one investor meetings. Presentations will be available via webcast on Alto's website with replay options available.
Alto Neuroscience (NYSE: ANRO) reported that its Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint. The treatment failed to show significant improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker. However, ALTO-100 maintained a favorable safety and tolerability profile.
The study, involving 301 adults with MDD across 34 U.S. sites, used the Montgomery-Åsberg Depression Rating Scale (MADRS) to assess changes in depressive symptoms. Despite the disappointing results, Alto Neuroscience remains committed to its mission and expects its strong cash position to support operations through 2027 and multiple near-term clinical milestones.
The company is also evaluating ALTO-100 in a Phase 2b study for bipolar depression and anticipates additional readouts for ALTO-203 and ALTO-300 in MDD in the first half of 2025.
Alto Neuroscience (NYSE: ANRO) has published a peer-reviewed analysis in The Journal of Clinical Psychiatry, revealing that baseline cognitive performance does not moderate response to standard antidepressants in major depressive disorder (MDD) patients. The study, involving 1,812 participants across four placebo-controlled trials, found that vortioxetine, despite its cognitive benefits, does not show greater efficacy in MDD patients with cognitive impairment.
This underscores the unmet need for effective treatments for MDD patients with cognitive impairment, who comprise up to 50% of the MDD population. Alto Neuroscience is developing ALTO-100, a first-in-class oral small molecule designed to enhance neural plasticity, as a potential treatment for this subgroup. Topline data from the Phase 2b MDD study of ALTO-100 is expected in October 2024.
Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in several upcoming investor conferences in September 2024. The company will host an Investor Day on September 9, focusing on ALTO-100 for Major Depressive Disorder, ahead of expected topline data in October 2024.
Alto will also present at the Baird Global Healthcare Conference (September 10-11), the Cantor Global Healthcare Conference (September 17-19), and the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (September 26). These events will feature presentations, one-on-one investor meetings, and a fireside chat, providing insights into Alto's progress and strategies.
Alto Neuroscience (NYSE: ANRO) reported Q2 2024 financial results and business highlights. Key points include:
- Completed enrollment of 301 patients in Phase 2b MDD study for ALTO-100; topline data expected in October 2024
- Initiated Phase 2 studies for ALTO-101 in schizophrenia, ALTO-203 in MDD with anhedonia, and ALTO-100 in bipolar depression
- Reported positive Phase 1 data on transdermal formulation of ALTO-101
- Strong cash position of $194 million expected to fund operations into 2027
- Q2 2024 R&D expenses increased to $13.2 million from $7.1 million in Q2 2023
- Net loss for Q2 2024 was $16.0 million compared to $8.7 million in Q2 2023
The company has five Phase 2 studies ongoing across four novel product candidates, with topline data expected before the end of 2026.
Alto Neuroscience (NYSE: ANRO) has received an $11.7 million funding award from Wellcome Trust to advance ALTO-100, a first-in-class small molecule, in a 200-patient Phase 2b study for bipolar depression. The study will leverage a cognitive biomarker previously identified in MDD and PTSD patients. This marks the first precision psychiatry trial in bipolar depression, an area of high unmet need.
ALTO-100 is believed to enhance neural plasticity and is currently in Phase 2b development for MDD, with results expected in October 2024. The new study for bipolar depression will use the same memory biomarker and design as the ongoing MDD study. The primary endpoint is the change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) over a six-week treatment period.
Alto Neuroscience (NYSE: ANRO) has completed enrollment in its Phase 2b study of ALTO-100 for major depressive disorder (MDD). The study includes 300 adult patients with and without a specific cognitive biomarker. Topline results are expected in October 2024. The randomized, double-blind, placebo-controlled study aims to determine ALTO-100's efficacy in MDD patients defined by an objective cognitive biomarker. The primary endpoint is the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) over a 6-week treatment period. Alto plans to host an investor day on September 9, 2024, focusing on ALTO-100 and providing information on study participants, mechanistic rationale, and the predictive cognitive test used for patient selection.
Alto Neuroscience announced the initiation of a Phase 2 trial for ALTO-101, a PDE4 inhibitor aimed at treating cognitive impairment in schizophrenia. The study, expected to conclude by the second half of 2025, will involve 70 adults and compare a transdermal formulation of ALTO-101 against a placebo. Previous Phase 1 trials showed positive cognitive effects and fewer adverse events compared to oral administration. CEO Amit Etkin highlighted the potential of ALTO-101 to improve cognitive function across various psychiatric disorders.
The primary outcome will measure the effect on theta band activity using EEG. This follows promising data presented at the SOBP Annual Meeting, affirming the relevance of EEG measures in assessing cognitive function in schizophrenia.
FAQ
What is the current stock price of Alto Neuroscience (ANRO)?
What is the market cap of Alto Neuroscience (ANRO)?
What is the mission of Alto Neuroscience?
What are some key products in Alto’s pipeline?
What recent financial achievements has Alto Neuroscience announced?
When can we expect data readouts for ALTO-100 and ALTO-300?
What is ALTO-101 and its current development status?
How does Alto's Precision Psychiatry Platform™ work?
What is Alto’s financial condition as of early 2024?
Which institutions were involved in Alto’s initial public offering?
What is the focus of ALTO-300’s development?
What significant appointments were made to Alto’s board in early 2024?
